Scientific article
Open access

Nouveautés dans la prise en charge de l’asthme

Published inRevue médicale suisse, vol. 18, no. 787, p. 1269-1274
Publication date2022-06-22

For general practitioners there have been important novelties in the treatment of asthma due to recent modifications of the international guidelines from Global Initiative for Asthma (GINA). In Step 1, use of short-acting beta2-agonists (SABA) without concomitant inhaled corticosteroids (ICS) as controller is no longer recommended for lack of efficacy and safety reasons. Instead, low dose ICS-formoterol as needed is recommended. In Step 5, in patients with severe uncontrolled asthma GINA recommends targeted biologic therapies like interleukin antibodies. Asthma patients presenting simultaneously with symptoms of chronic obstructive pulmonary disease (COPD) should receive treatment containing ICS. Independent of the current corona pandemic, GINA recommendations stay in place.

  • Administration, Inhalation
  • Adrenal Cortex Hormones / therapeutic use
  • Anti-Asthmatic Agents / therapeutic use
  • Asthma / drug therapy
  • Formoterol Fumarate / therapeutic use
  • Humans
  • Pulmonary Disease, Chronic Obstructive / drug therapy
Citation (ISO format)
LEUPPI, Jörg D et al. Nouveautés dans la prise en charge de l’asthme. In: Revue médicale suisse, 2022, vol. 18, n° 787, p. 1269–1274. doi: 10.53738/REVMED.2022.18.787.1269
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation01/09/2024 7:24:41 PM
First validation03/18/2024 2:50:20 PM
Update time03/18/2024 2:50:20 PM
Status update03/18/2024 2:50:20 PM
Last indexation03/18/2024 2:50:40 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack